The Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies

Overview

Journal Int J Mol Sci

Publisher MDPI

Date 2025 Jan 25

PMID 39859381

Authors

Yuganthini Vijayanathan

Ivy A W Ho

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is an aggressive brain tumor characterized by extensive metabolic reprogramming that drives tumor growth and therapeutic resistance. Key metabolic pathways, including glycolysis, lactate production, and lipid metabolism, are upregulated to sustain tumor survival in the hypoxic and nutrient-deprived tumor microenvironment (TME), while glutamine and tryptophan metabolism further contribute to the aggressive phenotype of GBM. These metabolic alterations impair immune cell function, leading to exhaustion and stress in CD8+ and CD4+ T cells while favoring immunosuppressive populations such as regulatory T cells (Tregs) and M2-like macrophages. Recent studies emphasize the role of slow-cycling GBM cells (SCCs), lipid-laden macrophages, and tumor-associated astrocytes (TAAs) in reshaping GBM's metabolic landscape and reinforcing immune evasion. Genetic mutations, including () mutations, () amplification, and () loss, further drive metabolic reprogramming and offer potential targets for therapy. Understanding the relationship between GBM metabolism and immune suppression is critical for overcoming therapeutic resistance. This review focuses on the role of metabolic rewiring in GBM, its impact on the immune microenvironment, and the potential of combining metabolic targeting with immunotherapy to improve clinical outcomes for GBM patients.

References

Long Y, Tao H, Karachi A, Grippin A, Jin L, Chang Y . Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Res. 2019; 80(3):499-509. DOI: 10.1158/0008-5472.CAN-19-1577. View

Oudard S, Arvelo F, Miccoli L, Apiou F, Dutrillaux A, Poisson M . High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer. 1996; 74(6):839-45. PMC: 2074724. DOI: 10.1038/bjc.1996.446. View

He K, Wang G, Zhao L, Cui X, Su X, Shi Y . Cinobufagin Is a Selective Anti-Cancer Agent against Tumors with EGFR Amplification and PTEN Deletion. Front Pharmacol. 2021; 12:775602. PMC: 8672866. DOI: 10.3389/fphar.2021.775602. View

Zhang Y, Zhao Y, Shen J, Sun X, Liu Y, Liu H . Nanoenabled Modulation of Acidic Tumor Microenvironment Reverses Anergy of Infiltrating T Cells and Potentiates Anti-PD-1 Therapy. Nano Lett. 2019; 19(5):2774-2783. DOI: 10.1021/acs.nanolett.8b04296. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

Khwairakpam A, Shyamananda M, Sailo B, Rathnakaram S, Padmavathi G, Kotoky J . ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment. Curr Drug Targets. 2014; 16(2):156-63. DOI: 10.2174/1389450115666141224125117. View

Husain Z, Seth P, Sukhatme V . Tumor-derived lactate and myeloid-derived suppressor cells: Linking metabolism to cancer immunology. Oncoimmunology. 2014; 2(11):e26383. PMC: 3881600. DOI: 10.4161/onci.26383. View

Liu Y, Li H, Hao Y, Huang L, Li X, Zou J . Tumor-Selective Nano-Dispatcher Enforced Cancer Immunotherapeutic Effects via Regulating Lactate Metabolism and Activating Toll-Like Receptors. Small. 2024; 21(1):e2406870. DOI: 10.1002/smll.202406870. View

Nachef M, Ali A, Almutairi S, Lee S . Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment. Front Immunol. 2021; 12:624324. PMC: 8089370. DOI: 10.3389/fimmu.2021.624324. View

10.

Daniele S, Giacomelli C, Zappelli E, Granchi C, Trincavelli M, Minutolo F . Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death. Sci Rep. 2015; 5:15556. PMC: 4616042. DOI: 10.1038/srep15556. View

11.

Zong W, Rabinowitz J, White E . Mitochondria and Cancer. Mol Cell. 2016; 61(5):667-676. PMC: 4779192. DOI: 10.1016/j.molcel.2016.02.011. View

12.

Fu W, Wang W, Li H, Jiao Y, Huo R, Yan Z . Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma. Front Immunol. 2020; 11:835. PMC: 7221162. DOI: 10.3389/fimmu.2020.00835. View

13.

Peng G, Wang Y, Ge P, Bailey C, Zhang P, Zhang D . The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin. J Exp Clin Cancer Res. 2021; 40(1):278. PMC: 8411541. DOI: 10.1186/s13046-021-02082-7. View

14.

Abdel-Wahab A, Mahmoud W, Al-Harizy R . Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019; 150:104511. DOI: 10.1016/j.phrs.2019.104511. View

15.

Strepkos D, Markouli M, Klonou A, Piperi C, Papavassiliou A . Insights in the immunobiology of glioblastoma. J Mol Med (Berl). 2019; 98(1):1-10. DOI: 10.1007/s00109-019-01835-4. View

16.

Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber S . T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clin Cancer Res. 2018; 24(17):4175-4186. PMC: 6081269. DOI: 10.1158/1078-0432.CCR-17-1846. View

17.

Gomes A, Ramos H, Soares J, Saraiva L . p53 and glucose metabolism: an orchestra to be directed in cancer therapy. Pharmacol Res. 2018; 131:75-86. DOI: 10.1016/j.phrs.2018.03.015. View

18.

van Zijl P, ROTHMAN D . NMR studies of brain 13C-glucose uptake and metabolism: present status. Magn Reson Imaging. 1995; 13(8):1213-21. DOI: 10.1016/0730-725x(95)02034-q. View

19.

Bashir M, Abdalla M, Shao C, Wang H, Bondzie-Quaye P, Almahi W . Dual inhibitory potential of ganoderic acid A on GLUT1/3: computational and insights into targeting glucose metabolism in human lung cancer. RSC Adv. 2024; 14(39):28569-28584. PMC: 11378701. DOI: 10.1039/d4ra04454a. View

20.

Eriksson M, Ambroise G, Ouchida A, Queiroz A, Smith D, Gimenez-Cassina A . Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism. Mol Cell Biol. 2017; 37(24). PMC: 5705820. DOI: 10.1128/MCB.00328-17. View